Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Blueprint Medicines Corporation | BLU-263 - (AZURE) | Non-advanced systemic mastocytosis (SM) | Phase 2 | Ongoing | oral | Immunology |
| Blueprint Medicines Corporation | GAVRETO (Pralsetinib) - AcceleRET | First-line RET-fusion non-small cell lung cancer (NSCLC) | Phase 3 | Trial Planned | Oral | Oncology |
| Blueprint Medicines Corporation | AYVAKIT (avapritinib) - (Voyager) | Gastrointestinal stromal tumors (GIST) | Phase 3 | Trial Completed | Oral | Oncology |
| Blueprint Medicines Corporation | GAVRETO (Pralsetinib) - AcceleRET | First-line RET-fusion non-small cell lung cancer (NSCLC) | Phase 3 | Trial Planned | Oral | Oncology |
| Blueprint Medicines Corporation | AYVAKIT (avapritinib) - (PIONEER) | Indolent and smoldering systemic mastocytosis (SM) | Phase 2 | Data Released | Oral | Immunology |
| Blueprint Medicines Corporation | AYVAKIT (avapritinib) - (Voyager) | Gastrointestinal stromal tumors (GIST) | Phase 3 | Trial Completed | Oral | Oncology |
| Bolt Biotherapeutics Inc. | Trastuzumab imbotolimod (BDC-1001) with Enhertu (pertuzumab) | HER2-positive breast, colorectal, endometrial, and gastroesophageal cancers | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Brainstorm Cell Therapeutics Inc. | NurOwn | Progressive Multiple Sclerosis (MS) | Phase 2 | Trial Completed | Intrathecal | Neurology |
